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Tacrolimus ointment is a topical calcineurin inhibitor for 
the treatment of atopic dermatitis. The primary objective 
of this open-label study was to assess the long-term safety 
of tacrolimus ointment. The primary end-point was the 
incidence of adverse events. Secondary end-points inclu-
ded the Eczema Area and Severity Index and a modified 
version of this index. A total of 466 children with atopic 
dermatitis, aged 2–15 years, applied 0.03% or 0.1% ta-
crolimus ointment twice daily for up to 29.5 months. Skin 
burning and pruritus were the most common application 
site events; their prevalence decreased over time. There 
was no increase in viral infections or other adverse events 
over time. Laboratory profiles were consistent with those 
reported in atopic populations. Substantial improvement 
in all efficacy end-points was observed by week 2 and 
maintained throughout the study. Long-term treatment 
with tacrolimus ointment is safe and effective in these pa-
tients with atopic dermatitis. Key words: atopic dermatitis; 
tacrolimus ointment; long-term; safety.
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Atopic dermatitis (AD) is a chronically relapsing in-
flammatory skin disease characterized by episodes of 
pruritus and excessive scratching that affects approxi-
mately 15% of children in developed countries (1, 2). 
The exact aetiology is unknown, but the disease is driven 
by the local release of pro-inflammatory mediators and 
cytokines (3).
Topical corticosteroids have been the mainstay of 
treatment; although in general they are safe when used 
according to guidelines, clinical response is not always 
satisfactory and long-term treatment carries the risk of 
local side-effects, such as skin atrophy and glaucoma 
(4, 5), and rare, systemic side-effects, such as abnormal 
adrenocortical function and growth retardation (6, 7). 
In addition, tachyphylaxis may develop, making alterna-
tive approaches to treatment advisable (8). 
Tacrolimus ointment is a macrolide calcineurin inhibi-
tor which down-regulates cutaneous T-cell activation. 
Tacrolimus was initially developed for the prevention 
of allograft rejection after organ transplantation (9, 10). 
The topical formulation was specifically developed for 
the treatment of AD. 
The short- and long-term safety and efficacy of tacro-
limus ointment in patients with AD have been demon-
strated in numerous studies; clinical trials including more 
than 17,000 patients have been conducted worldwide 
(Astellas Pharma Europe Ltd, data on file). These trials 
have shown that both the 0.1% and 0.03% formulations 
are efficacious and well tolerated by adult and paediatric 
patients alike (11–20). The most common side-effects 
are skin burning and pruritus, which are mainly mild to 
moderate and decrease after the first days of treatment. 
Tacrolimus ointment does not cause thinning of the 
skin (21) and can be used safely on the more vulnerable 
regions of the skin, such as the face and neck. Systemic 
absorption of the ointment is minimal (22).
A US 12-month study previously investigated the 
long-term safety of 0.1% tacrolimus ointment twice 
daily in children with AD aged 2–15 years (17). The 
present study is the first European long-term tacrolimus 
ointment study in children. As AD is chronic or recur-
rent in most patients, treatment periods of up to 29.5 
months were covered. 
MATERIALS AND METHODS
Study design
The primary aim of this long-term, open-label, non-compara-
tive, phase IIIb study was to assess the long-term safety of 
0.03% and 0.1% tacrolimus ointment in children with AD 
aged 2–15 years. The study was conducted at 39 centres in 11 
European countries between October 2000 and April 2003. The 
ethics committee from each centre reviewed the protocol and 
granted approval prior to the start of the study. Informed consent 
was provided by parents and guardians, and by the children 
themselves if they were considered mature enough. 
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The originally planned duration of study was 12 months. An 
extension period was added defining the end of study as the next 
scheduled visit following the launch of tacrolimus ointment in 
the patient’s country of residence (but not later than April 2003 
in countries without launch).
The study consisted of visits at baseline (day 1), at weeks 2 
and 4, months 3, 6, 9 and 12 and, if applicable, every 3 months 
thereafter until the end of study.
Patient selection
Male and female patients with AD, aged 2–15 years, were enrolled 
in the study. All participants had previously taken part in a 
3-week comparative trial with a treatment regimen of 0.03% 
tacrolimus ointment once or twice daily or 1% hydrocortisone 
acetate ointment twice daily (20). In this precursor study, all 
patients were diagnosed with AD based on the criteria of Hanifin 
& Rajka (23). At baseline, approximately 50% of patients had 
moderate and 50% had severe AD following the severity grading 
of Rajka & Langeland (24). The interim period between the end 
of the precursor study and the beginning of the present study 
was at least one week. 
Treatment plan
A thin coat of tacrolimus ointment was applied twice daily to 
affected areas during episodes of active disease. patients were 
initially treated with 0.03% tacrolimus ointment for 2 weeks 
or until clearance of lesions, whichever occurred first. If one 
or more of the treated lesions did not respond satisfactorily 
within 2 weeks of treatment, the patient was provided with 0.1% 
tacrolimus ointment. The respective lesions were then treated 
with 0.1% tacrolimus ointment for 2 weeks or until clearance 
of lesions, whichever occurred first. If any of the lesions treated 
with 0.1% tacrolimus ointment did not respond satisfactorily 
within 2 weeks of treatment, the patient could be excluded from 
the study at the investigator’s discretion. 
Prohibited therapies included topical and systemic cortico-
steroids for the treatment of AD, other investigational drugs, 
UV light therapy and non-steroidal immunosuppressants. The 
washout phase for these therapies ranged from a minimum of 
5 days (for topical and systemic corticosteroids) to a maximum 
of 6 weeks (for UV light therapy) prior to the start of the study. 
The washout period for non-steroidal immunosuppressants and 
other investigational drugs was 2 and 4 weeks, respectively. 
Restricted therapies included systemic non-steroidal anti-
 inflammatory drugs (≤ 2 weeks of treatment within any 3-month 
period) and non-medicated emollients (not to be applied to the 
treatment area within ≤ 2 hours of study drug application; the 
same emollient was to be used throughout the study). 
Assessments
Safety assessments during the study included monitoring of adverse 
events and clinical laboratory assessments. The primary end-
point of the study was the incidence of adverse events, classified 
as application and non-application adverse events. An adverse 
event was defined as any undesirable experience that occurred 
to a patient during the study, regardless of whether it was related 
to the study drug. Adverse events assessed by the investigator as 
being causally related to the study drug were defined as all adverse 
events with highly probable, probable, possible or not assessable 
causal relationship to the study drug or adverse events where the 
assessment of the relationship to study drug was missing.
Secondary safety end-points were laboratory assessments, 
including haematology, blood chemistry profile and renal and 
hepatic function, and were performed at day 1, months 6 and 
12, and at the end of study. 
The patient’s height and weight was recorded at day 1, months 
6, 12 and 18, and at the end of study. 
Efficacy end-points were assessed on each visit and included 
changes in Eczema Area and Severity Index (EASI) (25) and 
modified EASI (mEASI) and their single components; the 
physician’s assessment of individual signs, the affected body 
surface area and the patient’s assessment of itch. 
The EASI is a composite score comprising ratings of the 
severity of erythema, oedema/induration/papulation, excoriations 
and lichenification weighted according to the estimated per-
centage of affected body surface area. The mEASI is identical 
to the EASI except that it includes an additional assessment of 
itch, one of the primary symptoms of AD (24). 
A physician assessed the therapeutic response of the disease to 
the treatment at every visit after day 1 as “satisfactory: yes/no” 
for each body region. 
Quality of life was measured at every study visit with the 
Infants’ Dermatitis Quality of Life Index (26) for children aged 
2–4 years and the Children’s Dermatology Life Quality Index 
(27) for children aged 5–15 years. 
Statistical analysis
In addition to the overall analysis of the study population, 
patients aged 2–6 years and patients aged 7–15 years were 
analysed separately. The evaluable population (intent-to-treat 
population) comprised patients who received at least one app-
lication of tacrolimus ointment. All data were summarized by 
descriptive statistics and frequency counts. Adverse events were 
coded according to a modified COSTART (coding symbols 
for the thesaurus of adverse event reaction terms) dictionary. 
Efficacy data were analysed using the Last Observation Carried 
Forward principle. 
RESULTS
Patient baseline information, disposition and characteristics
A total of 466 patients (233 per age group; 2–6 and 
7–15 years) were enrolled. The mean baseline per-
centage affected body surface area as a percentage of 
the total body surface area (affected BSA) was 30.7% 
(SD 24.2). The mean EASI and mEASI scores for 
all patients were 15.8 (SD 12.5) and 20.5 (SD 16.1), 
respectively. patient’s assessment of itch, using a 10 
cm visual analogue scale (VAS), was 5.4 (SD 2.9). All 
patients received at least one dose of 0.03% tacroli-
mus ointment. The mean interval between precursor 
study and the present study was 6.6 months (SD 3.9). 
Patient disposition is shown in Table I: 138 patients 
(29.6%) did not complete the study; the majority of 
them discontinued for administrative reasons (e.g. 
lost to follow-up, withdrawal of consent). Thirty-eight 
patients (8.2%) discontinued due to lack of efficacy and 
16 (3.4%) due to an adverse event. Fifty-nine patients 
(12.6%) discontinued before month 12, 21 patients 
(4.5%) did not give consent for the extension period.
There was a slight excess of female patients. Over 80% 
of patients were Caucasian. The younger age group had 
a higher baseline disease severity in all clinical efficacy 
parameters and quality of life scores. 
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Study duration and treatment days
The mean study duration was 16.3 months (SD 6.4) 
(median 17.9 months; range 1–897 days (29.5 months)). 
On average, patients used tacrolimus ointment on 63.7% 
of study days. A total of 347 patients (74.5%) used 0.1% 
tacrolimus ointment at least once in the study, but only 
a quarter of these patients used this concentration on 
approximately 50% or more of study days. 
Safety
The most common adverse events (irrespective of 
causality) are shown in Table II.
The most common application site adverse events 
overall were pruritus and skin burning. Most of these 
events were considered to be causally related to the 
study drug (Table III); their prevalence was highest 
during the first weeks of treatment and then decreased 
over time (Fig. 1). 
The prevalence rates of other application site adverse 
events, including viral infections (Fig. 2), were low and did 
not change substantially over time. The majority (85.6%) 
of these events were of mild to moderate severity. 
The most common non-application site events were 
seasonal infections, such as flu-syndrome (Table II), 
which were mainly considered to be unrelated to 
tacrolimus ointment (Table III). Their prevalence did 
not increase over time. 
Overall, a higher percentage of younger than 
older patients experienced adverse events, which was 
mainly due to the higher incidence of cutaneous and 
non-cutaneous infections in the younger age group. 
Most events (65.1%) in the category “skin infection” 
(non-specific cutaneous infections not defined by an 
individual COSTART term) were classified by the 
investigator as bacterial infections. 
Twenty-three patients (4.9%) suffered from herpes 
simplex during the study; in 16 patients (3.4%), a causal 
Table I. Patient disposition – number of patients (%)




Number of patients 466 233 233
Completed study 328 (70.4) 164 (70.4) 164 (70.4)
Discontinued from study 138 (29.6) 69 (29.6) 69 (29.6)
Reason for premature 
discontinuation from study:
Administrative reasonsa 79 (17.0) 35 (15.0) 44 (18.9)
Lack of efficacy of treatment 38   (8.2) 22   (9.4) 16   (6.9)
Adverse event 16   (3.4) 11   (4.7) 5   (2.1)
Otherb 5   (1.1) 1   (0.4) 4   (1.7)
aFor example, lost to follow-up, withdrawal of consent, no consent for 
extension period, non-compliance.
bFor example, use of prohibited medication, erroneous enrolment.
Table II. Incidence of most commona adverse events irrespective 





Number of patients 466 233 233
Overall adverse events 400 (85.8) 203 (87.1) 197 (84.5)
Application site adverse events
Overall 328 (70.4) 171 (73.4) 157 (67.4) 
pruritus 141 (30.3) 75 (32.2) 66 (28.3)
Skin burning 131 (28.1) 56 (24.0) 75 (32.2)
Skin infection 126 (27.0) 77 (33.0) 49 (21.0)
Lack of drug effect 82 (17.6) 42 (18.0) 40 (17.2)
Varicella infectionsb 33   (7.1) 27 (11.6) 6   (2.6)
Chickenpox 31   (6.7) 27 (11.6) 4   (1.7)
Shingles 2   (0.4) 0   (0.0) 2   (0.9)
Non-application site adverse events
Overall 329 (70.6) 178 (76.4) 151 (64.8) 
Flu syndrome 147 (31.5) 81 (34.8) 66 (28.3)
Asthma 54 (11.6) 34 (14.6) 20   (8.6)
Gastroenteritis 51 (10.9) 34 (14.6) 17   (7.3)
Allergic reaction 48 (10.3) 29 (12.4) 19   (8.2)
Fever 47 (10.1) 32 (13.7) 15   (6.4)
pharyngitis 47 (10.1) 24 (10.3) 23   (9.9)
bronchitis 42   (9.0) 31 (13.3) 11   (4.7)
Cough increased 41   (8.8) 28 (12.0) 13   (5.6)
Otitis media 36   (7.7) 25 (10.7) 11   (4.7)
aAny adverse event experienced by at least 10% of patients in either age group 
bThe COSTART term “herpes zoster” codes for both chickenpox and 
shingles. As herpes zoster is the medical name for shingles, we prefer to 
use the term “varicella infections”.
Fig. 1. Prevalence of skin burning and pruritus 
over time, regardless of relationship to study 
drug. W, week; M, month.
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relationship to the study drug was reported. Eight patients 
(1.7%) had recurring episodes of herpes simplex. Four 
patients (0.9%) were classified by investigators as cases 
of eczema herpeticum, a condition typically affecting 
patients with AD (28). Two cases were rated as mild and 
2 cases were rated as severe; a possible causal relation-
ship to study drug was reported in 3 cases. Thirty-eight 
patients (8.2%) were affected by varicella infections 
(chickenpox or shingles) at some stage in the study; in 
7 patients (1.5%) this condition was assessed as being 
causally related to the study drug. The majority of affect-
ed patients were younger patients who had chickenpox; 
5 patients (1.1%) were diagnosed as cases of shingles. 
Seventeen patients (3.6%) were diagnosed with “skin 
neoplasm benign” (all cases were classified as warts); in 
8 patients (1.7%), a causal relationship to the study drug 
was reported. No malignant skin neoplasms occurred. 
Fourteen patients (3.0%) were diagnosed with mol-
luscum contagiosum, a causal relationship to study drug 
was reported in 7 patients (1.5%).
A total of 33 patients (7.1%) experienced a serious ad-
verse event during the study (Table IV). Eleven patients 
(2.4%) experienced 14 serious adverse events which 
were assessed by the investigator as being causally 
related to the study drug (10 events of skin infection, 3 
events of herpes simplex and one event of herpes zoster; 
all but one were present on the application site). 
Adverse events leading to treatment discontinuation 
and assessed as being causally related to study drugs were 
reported in 15 patients (3.2%). All but one of these adverse 
events were application site events such as skin infection 
and pruritus. A 6-year-old boy had leukopaenia at month 
6 (white blood cell count 3.0×109/l) and was withdrawn 
from the study. There were no accompanying symptoms 
of illness reported and this case was not considered to 
be a serious adverse event. Subsequently the patient’s 
leukocyte count was confirmed to be normal (5.8×109/l) 
by the patient’s paediatrician. Leukopaenia has rarely 
been reported (isolated cases only) as an adverse event in 
tacrolimus ointment clinical trials to date.
Table III. Incidence of most commona adverse events assessed by 
the investigator as causally relatedb – number of patients (%)




Number of patients 466 233 233
Skin burning 124 (26.6) 52 (22.3) 72 (30.9)
pruritus 123 (26.4) 64 (27.5) 59 (25.3)
Skin infection 75 (16.1) 42 (18.0) 33 (14.2)
Lack of drug effect 40   (8.6) 17   (7.3) 23   (9.9)
Skin erythema 22   (4.7) 9   (3.9) 13   (5.6)
Folliculitis 19   (4.1) 3   (1.3) 16   (6.9)
Herpes simplex 16   (3.4) 8   (3.4) 8   (3.4)
Application site reaction 12   (2.6) 4   (1.7) 8   (3.4)
Rash 10   (2.1) 6   (2.6) 4   (1.7)
Skin neoplasm benign 8   (1.7) 5   (2.1) 3   (1.3)
Flu syndrome 7   (1.5) 1   (0.4) 6   (2.6)
pustular rash 7   (1.5) 5   (2.1) 2   (0.9)
aAt least 2% of patients in any age group – results refer to overall 
(application- and non-application site) events.
b”Causally related” was assigned if the investigator assessed the event as 
having a highly probable, probable, possible, or not assessable relationship to 
the study drug or if the assessment for relationship to study drug was missing.
Table IV. Serious adverse events irrespective of causality, overall 
and by age group – number of patients (%)




Number of patients 466 233 233
Total 33 (7.1) 20 (8.6) 13 (5.6)
Skin infection 11 (2.4) 8 (3.4) 3 (1.3)
Asthma 7 (1.5) 5 (2.1) 2 (0.9)
Herpes simplex 4 (0.9) 2 (0.9) 2 (0.9)
Accidental injury 3 (0.6) 2 (0.9) 1 (0.4)
Allergic reaction 2 (0.4) 2 (0.9) 0 (0.0)
bronchitis 1 (0.2) 0 (0.0) 1 (0.4)
Cellulitis 1 (0.2) 1 (0.4) 0 (0.0)
CNS neoplasia benign 1 (0.2) 0 (0.0) 1 (0.4)
Conjunctivitis 1 (0.2) 1 (0.4) 0 (0.0)
Constipation 1 (0.2) 0 (0.0) 1 (0.4)
Drug dependence 1 (0.2) 0 (0.0) 1 (0.4)
Dyspepsia 1 (0.2) 1 (0.4) 0 (0.0)
Oesophagitis 1 (0.2) 0 (0.0) 1 (0.4)
Herpes zoster 1 (0.2) 0 (0.0) 1 (0.4)
Lack of drug effect 1 (0.2) 0 (0.0) 1 (0.4)
pharyngitis 1 (0.2) 1 (0.4) 0 (0.0)
Sinusitis 1 (0.2) 0 (0.0) 1 (0.4)
Surgical treatment 1 (0.2) 0 (0.0) 1 (0.4)
Fig 2. prevalence of application-site viral 
skin infections and conditions associated with 
viral skin infections over time, regardless of 
relationship to study drug. W, week; M, month.
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No cases of growth retardation or skin atrophy were 
reported by investigators. 
Laboratory measurements showed eosinophil levels 
greater than the reference range in approximately 40% 
of the study population throughout the study. There 
were no marked changes of mean laboratory values 
over time. Except for the reported case of leukopaenia, 
no changes in laboratory parameters during the study 
suggested a safety concern.
Efficacy 
There was similar improvement in all efficacy end-
points in both age groups. Substantial improvement 
in all clinical efficacy parameters was notable after 
2 weeks of therapy, continued until month 6 and was 
maintained during the rest of the study (Fig. 3). There 
was no indication of a decrease in efficacy. According 
to the physician’s assessment of therapeutic response, 
a substantial proportion (73.0–77.0%) of patients expe-
rienced at least a satisfactory response to treatment by 
the end of study (head and neck: 77.0%; trunk: 73.0%; 
upper limbs: 75.8%; lower limbs: 74.0%). 
The clinical efficacy data were confirmed by the qua-
lity of life measurements; a substantial improvement in 
quality of life was shown between day 1 and week 2, 
with further improvement by month 6 and maintenance 
of these levels throughout the study in both age groups.
DISCUSSION
In this long-term study with a mean duration of 16.3 
months, 0.03% and 0.1% tacrolimus ointment were 
shown to be well tolerated and effective for the treat-
ment of AD in children aged 2–15 years for periods up 
to 29.5 months. The long-term safety and efficacy profile 
of tacrolimus ointment was similar to that of a US 12-
month paediatric study including 255 patients (17).
The majority of adverse events related to tacrolimus 
ointment occurred at the application site, the most com-
mon ones being skin burning and pruritus, which were 
transient events of mainly mild to moderate severity. 
Adverse events not caused by local irritation of the 
skin were related mainly to seasonal infections such as 
flu syndrome, paediatric diseases and illnesses generally 
associated with AD and atopy, such as asthma. The 
higher incidence of adverse events in the younger age 
group can be explained by the increased susceptibility 
of this age group to infections and by their higher di-
sease severity. 
No systemic toxic effects of tacrolimus ointment were 
apparent. Growth retardation or skin atrophy, potential 
side-effects of long-term use of topical corticosteroids 
(5, 7), were not reported for any patient. 
Although incidence rates vary between studies, 
patients with AD tend to show a disposition towards 
bacterial and viral infections (28–40).
The overall incidence of herpes simplex in this study 
was 4.9%. In an epidemiological survey of 2514 nur-
sery school children, 8.3% of children with AD had 
recurrent cutaneous herpes simplex infection (37). In 
a prospective study of 179 children with AD studied 
over a period of 2.75 years (mean observation period: 
1.5 years), herpes simplex was reported in 5.6% of 
patients (38). 
In the present study, varicella infections were re-
ported for 8.2% of patients, which were mainly cases 
of chickenpox occurring in the younger age group; 5 
patients (1.1%) were diagnosed as cases of shingles. In-
cidence data on shingles in children with AD are scarce. 
Fig. 3. Efficacy scores over time. (a) Eczema Area and Severity Index 
(EASI) score; (b) mEASI (modified EASI) score; (c) % body surface area 
(bSA) affected; (d) patient’s assessment of itch. Sample sizes: D1 = 466; 
W2 = 447; M6(LOCF) = 463; EOS(LOCF) = 466. LOCF, last observation 
carried forward; D, day, W, week; EOS, end of study (mean study duration: 
16.3 months).
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In healthy children, yearly incidence rates of 0.1% to 
0.2% have been reported (39). In a survey of 955 adults 
with present or past AD, 7% with active disease had a 
history of herpes zoster (32).
In the present study, 3.6% of patients were diag-
nosed with warts. Epidemiological data on warts are 
scarce and inconsistent; rates between 1.8% and 17% 
in children with AD have been recorded (37, 40, 41). 
The above quoted survey of nursery school children 
reported a prevalence of warts in 13.6% of children 
with AD compared with 8.2% of children without AD 
(37). These results are contradicted by a birth cohort 
study of 9263 11-year-old school children; warts were 
observed in 1.8% of children with AD and in 4.0% of 
children without AD (41). 
Molluscum contagiosum was diagnosed in 3.0% of 
the study population. There are few incidence data on 
this condition but it is seen as a typical complication 
of AD (30).
bacterial colonization of the skin, especially with 
S. aureus, is common in AD and can exacerbate the 
disease (33). The carrier rate of S. aureus has been 
shown to be between 85% and nearly 100% in lesions 
of patients with AD (35–37). In a paediatric study of 190 
patients with AD followed over a 2.5-year period (mean 
observation period: 13 months), 40% of patients ex-
perienced bacterial skin infections (36). In the present 
study, the overall incidence of skin infection (COSTART 
term) was 29.2%; 65.1% of cases were classified as 
bacterial infections. 
The incidence of flu syndrome, the most common 
adverse event in the present study, was 31.5%. In a US 
survey, the prevalence of flu syndrome over a 1-year 
period was 34.8% for the general population and 46.3% 
for children from 5 to 17 years of age (42). 
The incidence rates of infections in the present study 
were in line with reported rates in the literature, sug-
gesting that the incidence rates in the study population 
reflect the epidemiology of infections in the atopic 
and general populations. However, one needs to 
acknowledge the limitations of retrospectively com-
paring incidence data from a non-comparative study 
with incidence data from studies comprising different 
patient populations. In addition, these populations may 
have been treated with topical corticosteroids (which 
are known to increase susceptibility to skin infections 
(43)) and may not be ideal comparators to assess 
an increased risk of infection in tacrolimus-treated 
patients. Furthermore, the data presented only document 
incidence, not extent of infection, and the theoretical 
risk that tacrolimus ointment may reduce skin resistance 
to infection leading to more extensive (not necessarily 
more common) infections cannot be assessed.
Only one patient (a 6-year-old boy with leukopaenia 
assessed as being causally related to study drug) was 
discontinued from the study because of abnormal la-
boratory values. Otherwise, no changes in laboratory 
parameters during the study suggested a safety con-
cern. Laboratory profiles were consistent with those 
previously reported in patients with AD; eosinophilia, 
a known feature of AD (3), was seen in approximately 
40% of patients throughout the study.
The efficacy results of this study are in line with 
findings from the previously quoted short- and long-
term trials. Even when considering the natural course 
of AD, the resolution of symptoms was considerable. 
There was no indication of tachyphylaxis; only a few 
patients discontinued due to lack of efficacy, and the ef-
fectiveness of tacrolimus ointment in study completers 
did not decrease over time. The clinical efficacy results 
were confirmed by considerable improvements in the 
quality of life of the study population. 
The population in the present study only included 
children over 2 years old. pharmacokinetic trials in 
younger children are currently being conducted and 
clinical trials are planned. A recent review of 12 AD 
patients younger than 2 years treated with 0.03% or 
0.01% tacrolimus ointment showed that all patients ex-
perienced an improvement in symptoms. No significant 
adverse effects were noted (44).
In conclusion, the results of the present study show 
that long-term treatment with 0.03% and 0.1% tacro-
limus ointment for periods up to 29.5 months is a safe 
and effective therapy for 2–15-year-old patients with 
AD. Local irritation seems to be the only adverse event 
clearly associated with tacrolimus ointment.
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